| Literature DB >> 28850101 |
Wipaporn Wongfieng1,2,3,4, Amonrat Jumnainsong5,6, Yaovalux Chamgramol7,8, Banchob Sripa9,10, Chanvit Leelayuwat11,12,13.
Abstract
The treatment of cancer through the induction of natural killer group 2, member D (NKG2D) ligands is of interest, but understanding of mechanisms controlling expression of individual ligand is limited. The major histocompatibility complex (MHC) class I chain related protein B (MICB) is a member of NKG2D ligands. We aimed to investigate the role of 3'-untranslated (3'-UTR) and 5'-untranslated regions (5'-UTR) in post-transcriptional regulation of MICB. Nine novel microRNAs (miRNAs) predicted to interact with 3'-UTR and 5'-UTR using TargetScan, RNAhybrid and miBridge were identified. Their regulation of 3'-UTR, 5'-UTR and both 3'- and 5'-UTR sequences of MICB were indicated by the reduction of luciferase activities of luciferase reporter constructs. Mutations of miRNA binding sites at 3'- and 5'-UTRs resulted in increased luciferase activities confirming the regulation of nine candidate miRNAs. In addition, overexpression of candidate miRNAs also down-regulated the expression of reporter constructs. Consequently, the overexpression and inhibition of candidate miRNAs lead to the decreased and increased. MICB protein expressions on the cells tested, respectively. This study has identified a new role of miRNAs in regulation of MICB expression via both 3'-UTR and 5'-UTR sequences applicable for cancer immunotherapy.Entities:
Keywords: 5′-UTR regulation; major histocompatibility complex (MHC) class I chain related protein B (MICB); microRNA; natural killer group 2, member D (NKG2D); natural killer group 2, member D (NKG2D) ligands
Year: 2017 PMID: 28850101 PMCID: PMC5615347 DOI: 10.3390/genes8090213
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
List of plasmid constructs.
| Plasmid Names | Information |
|---|---|
| pMICB_3U | Wild type 3′-UTR of MICB |
| pMICB_5U | Wild type 5′-UTR of MICB |
| pMICB_3U_5U | Wild type 3′- and 5′-UTR of MICB |
| pMut_Known+6 Novel miRNAs | mutated both known and novel miRNAs binding sites at 3′-UTR (no inserted 5′-UTR) |
| pMut_Known miRNAs | mutated only known miRNAs binding sites 3′-UTR (no inserted 5′-UTR) |
| pMut_320a | mutated binding site of only miR-320a 5′-UTR (no inserted 3′-UTR) |
| pMut_miR320a+5 Novel miRNAs | mutated binding sites of all candidate miRNAs 5′-UTR (no inserted 3′-UTR) |
| pMut_Known_3U_M5U | mutated binding sites of known miRNAs on 3′-UTR and mutated binding sites of only candidate miRNAs on 5′-UTR |
| pMut_Known+6 Novel miRNAs_3U_M5U | mutated both binding sites of known and candidate miRNAs on 3′-UTR and mutated binding sites of only candidate miRNAs on 5′-UTR |
Novel candidate microRNAs (miRNAs) binding sites at 5′-untranslated region (UTR) and 3′-UTR of MHC class I chain related protein B (MICB).
| miRNA | 5′-UTR | 3-′UTR | ||||
|---|---|---|---|---|---|---|
| Seed Sequence | Binding Sequence | Free Energy (Kcal/mol) | Seed Sequence | Binding Sequence | Free Energy (Kcal/mol) | |
| miR-302c | UUCAGUGG | 77UCGCUGAG a | −21.7 | AAGUGC | 736GCACUU a,b,c | −20.3 |
| miR-320a | UGAGAGGG | 51UCUUCUCA a | −24.4 | AAAGCU | 1103AGCUUU a,b,c | −24.7 |
| AAGCUGG | 60CCGGUUU b | −25.8 | ||||
| miR-320b | UGAGAGGG | 51UCUUCUCA a | −24.4 | AAAGCU | 1103AGCUUU a,b,c | −24.7 |
| AAGCUGG | 60CCGGUUU b | −25.8 | ||||
| miR-320c | UGAGAGGG | 51UCUUCUCA a | −21.0 | AAAGCU | 1103AGCUUU a,b,c | −24 |
| AAGCUGG | 60CCGGUUU b | −22.4 | ||||
| miR-320d | UGAGAGGA | 51UCUUCUCA a | −21.3 | AAAGCU | 1103AGCUUU a,b,c | −24.3 |
| AAGCUGG | 60CCGGUUU b | −22.7 | ||||
| miR-542-3p | UAACUGAA | 69UUCAGUUG a | −18.1 | GUGACA | 671UGUCAC a,b,c | −21.7 |
| miR-641 | AGUCACCU | 30AGGUGACU a | −24.4 | AAGACA | 526AUGUCU a,b,c | −16.3 |
| AAGAC | 51GUCUU b | −21.3 | ||||
| miR-661 | GCCUGCGC | 26GCGCAGGU a | −30.8 | GCCUGG | 677CCAGGC a,b,c | −26.8 |
| GCCUGGG | 56CUCACCGGU b | −30.5 | ||||
| miR-940 | CCCCGCUC | 19GAGCGGGG a | −27.6 | AGGCAG | 32,881CUGCCU a,b,c | −28.5 |
| GGCAGGGCC | 75GGCCACUCCU b | −26.3 | ||||
a analyzed by miBridge; b analyzed by RNA hybrid; c analyzed by TargetScan.
Figure 1The endogenous expression of protein and messenger RNA (mRNA) of MHC class I chain related protein B (MICB) as well as candidate microRNAs (miRNAs) in various human cancer cell lines. (A) The protein expression levels of MICB were divided by mRNA expression levels of MICB to show ratio between protein and mRNA expression; (B) Endogenous expression levels of nine candidate miRNAs were measured in human cancer cell lines by quantitative real-time polymerase chain reaction (qRT-PCR) (candidate miRNAs that were not detected are not shown). The expression levels were normalized to miR-16. The results are depicted as mean ± standard error of mean (S.E.M). Relative expression was calculated as: 2ΔCt, where ΔCT = CTgivenmiRNA − CTmiR-16.
Figure 2The effect of 3’-and 5’-untranslated regions (UTRs) of MICB on luciferase activity. (A) The constructs used for transfection in these experiments are represented. Luciferase gene alone is an empty control vector. Plasmids containing3′-UTR, 5′-UTR and both 3′- and 5′-UTR inserts are abbreviated with pMICB_3U, pMICB_5U and pMICB_3U_5U, respectively; (B) Effect of 3′-UTR and 5′-UTR of MICB on luciferase expression when these vectors were transfected to 239T cells are shown. Firefly luciferase activity was normalized with Renilla luciferase activity to give relative expression and subsequently normalized to the activity of control reporter. Results are depicted as mean ± S.E.M, n = 3 experiments.
Figure 3Candidate miRNAs directly interacted to 3’-UTR and 5’-UTR of MICB. (A) The predicted binding sites of candidate miRNAs were mutated by PCR directed mutagenesis and were confirmed by DNA sequencing as shown; (B) Relative luciferase activity after transiently transfected with a luciferase reporter fused to a 3′-UTR of MICB (pMICB_3U), the mutated 3′-UTR of MICB for the binding sites of known miRNAs (pMut_Known miRNAs_3U), the mutated 3′-UTR of MICB for the binding sites of both known miRNAs and novel miRNAs (pMut_Known+6 Novel miRNAs_3U) or luciferase gene alone (empty control vector) into 293T cells; (C) Relative luciferase activity after overexpressing candidate miRNAs in 293T cell and co-transfected with a luciferase reporter fused to a 3′-UTR of MICB (pMICB_3U); (D) Relative luciferase activity after transiently transfected with a luciferase reporter fused to a 5′-UTR of MICB (pMICB_5U), a mutated binding site of only miR-320a (pMut_320a), a mutated binding sites of all candidate miRNAs (pMut_miR320a+5 Novel miRNAs) or luciferase gene alone (empty control vector) into 293T cells; (E) Relative luciferase activity after overexpressing candidate miRNAs in 293T cell and co-transfected with a luciferase reporter fused to a 5′-UTR of MICB (pMICB_5U); (F) Mutated binding sites of only candidate miRNAs on 5′-UTR (pMut_Known _3U_M5U) and, mutated both binding sites of known and candidate miRNAs on 3′-UTR and mutated binding sites of only candidate miRNAs on 5′-UTR (pMut_Known+6 Novel miRNAs_3U_M5U); (G) Relative luciferase activity after overexpressing candidate miRNAs in 293T cell and co-transfected with a luciferase reporter fused to both 3′- and 5′-UTR (pMICB_3U_5U). Firefly luciferase activity was normalized with Renilla luciferase activity and subsequently normalized to the activity of control reporter. Results are depicted as mean ± S.E.M, n = 3 experiments.
Figure 4Inhibition of MICB expression on HeLa after transfection of miRNA mimics. (A) Fold change expression of miRNA compared to miRNA mimic control or mock (mock is transfected cells with irrelevant miRNA mimic). miRNAs were detected after transient transfection of 5 μg miRNA mimic control, miR-302c mimic, miR-320a mimic, miR-542-3p mimic, miR-641 mimic or miR-940 mimic into Hela cells. The expression levels were normalized to miR-16 expression. Fold change expression was calculated as: 2−ΔΔCt, where ΔΔCT = ΔCT (mimic miRNA transfected sample) − ΔCT (untransfected sample). (B) The expression of surface MICB was measured by flow cytometry after transfected with miRNA mimics into HeLa cells. The data shown in percentages of inhibition of MICB expression in mean fluorescence intensity (MFI) calculated from three experiments; (C) the histogram of flow cytometry is presented; the upper panel was stained with isotype control and the lower panel was stained with anti-MICB antibody. Resultsare depicted as mean ± S.E.M, n = 3 experiments.
Figure 5Increased MICB expression on KKU-214 cells after transfection with antisense miRNAs. (A) Fold change expression of miRNAs compared to the miRNA scramble control or mock (mock is transfected cells with irrelevant antisense-miRNA), miRNA expressions were presented after transient transfection of 500 nM miRNA scramble control (labelled as negative control in C), antisense-miR-320a or antisense-miR-940 into KKU-214 cells. The expression levels were normalized to miR-16. Fold change expression was calculated as: 2−ΔΔCt, where ΔΔCT = ΔCT (antisense-miRNA transfected sample) − ΔCT (untransfected sample); (B) The expression of surface MICB was measured by flow cytometry after transfected with miRNA scramble control, anti-miR320a or anti-miR940 into KKU-214 cells. The percentages of increasing MICB expressions based on the MFI calculated from three experiments; (C) Upper histogram was stained with isotype control and lower histogram was stained with anti-MICB antibody. Results are depicted as mean ± S.E.M, n = 3 experiments.